Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
$2.75
$2.77
$1.69
$3.29
$493.60M2.031.27 million shs344,844 shs
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
$3.21
-2.1%
$3.93
$2.42
$5.81
$82.47M1.1767,142 shs9,197 shs
Vaccinex, Inc. stock logo
VCNX
Vaccinex
$5.01
+0.8%
$7.55
$4.43
$100.80
$6.16M0.7411,566 shs3,498 shs
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$1.76
-1.1%
$2.35
$1.46
$3.26
$247.19M2.332.15 million shs712,941 shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
0.00%-1.08%+10.44%+15.55%+8.70%
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
-2.13%+2.23%-17.27%-27.70%-8.55%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
+0.91%+3.41%-35.46%-39.43%-93.80%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
-1.12%-1.12%-16.59%-28.46%-20.36%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
1.1892 of 5 stars
3.53.00.00.01.10.80.0
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
2.102 of 5 stars
3.55.00.00.00.00.80.0
Vaccinex, Inc. stock logo
VCNX
Vaccinex
N/AN/AN/AN/AN/AN/AN/AN/A
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
3.5682 of 5 stars
3.52.00.04.20.02.50.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
3.00
Buy$4.3357.58% Upside
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
3.00
Buy$10.00211.53% Upside
Vaccinex, Inc. stock logo
VCNX
Vaccinex
N/AN/AN/AN/A
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
3.00
Buy$4.88176.99% Upside

Current Analyst Ratings

Latest XERS, ABUS, ETON, and VCNX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/4/2024
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$4.00
3/28/2024
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$5.00
3/7/2024
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$5.50 ➝ $6.00
3/1/2024
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$6.00 ➝ $5.00
3/1/2024
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
$18.14M27.21N/AN/A$0.63 per share4.37
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
$31.64M2.61$0.00 per share1,016.96$0.60 per share5.35
Vaccinex, Inc. stock logo
VCNX
Vaccinex
$570K10.80N/AN/A($2.59) per share-1.93
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
$163.91M1.51N/AN/A($0.05) per share-35.20

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
-$72.85M-$0.44N/AN/AN/A-401.57%-57.82%-43.42%5/2/2024 (Confirmed)
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
-$940K-$0.03N/AN/A-2.96%-6.21%-3.17%5/9/2024 (Estimated)
Vaccinex, Inc. stock logo
VCNX
Vaccinex
-$20.25M-$100.86N/AN/AN/A-2,667.31%-571.70%5/20/2024 (Estimated)
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
-$62.26M-$0.45N/AN/AN/A-37.98%-610.76%-19.15%5/14/2024 (Estimated)

Latest XERS, ABUS, ETON, and VCNX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024N/A
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
-$0.10N/A+$0.10N/AN/AN/A  
4/2/2024Q4 2023
Vaccinex, Inc. stock logo
VCNX
Vaccinex
N/A-$39.40-$39.40-$39.40N/AN/A
3/14/2024Q4 2023
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
-$0.04-$0.09-$0.05-$0.09$7.70 million$7.31 million    
3/6/2024Q4 2023
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
-$0.09-$0.10-$0.01-$0.10$45.50 million$44.39 million    
2/29/2024Q4 2023
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
-$0.12-$0.12N/A-$0.12$4.74 million$2.15 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
N/AN/AN/AN/AN/A
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
N/AN/AN/AN/AN/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
N/AN/AN/AN/AN/A
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
N/A
5.87
5.87
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
N/A
1.65
1.60
Vaccinex, Inc. stock logo
VCNX
Vaccinex
N/A
0.57
0.57
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
49.27
1.64
1.23

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
43.79%
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
27.86%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
50.11%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
42.75%

Insider Ownership

CompanyInsider Ownership
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
5.40%
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
13.16%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
51.50%
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
4.36%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
73179.49 million169.80 millionOptionable
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
3025.69 million22.31 millionOptionable
Vaccinex, Inc. stock logo
VCNX
Vaccinex
381.23 million598,000Optionable
Xeris Biopharma Holdings, Inc. stock logo
XERS
Xeris Biopharma
377140.45 million134.33 millionOptionable

XERS, ABUS, ETON, and VCNX Headlines

SourceHeadline
Xeris Biopharma Holdings, Inc.s (NASDAQ:XERS) top owners are retail investors with 51% stake, while 45% is held by institutionsXeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) top owners are retail investors with 51% stake, while 45% is held by institutions
finance.yahoo.com - April 5 at 12:23 PM
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - April 3 at 6:23 PM
Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceXeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference
finance.yahoo.com - April 2 at 8:50 AM
Xeris Biopharma (NASDAQ:XERS) Now Covered by OppenheimerXeris Biopharma (NASDAQ:XERS) Now Covered by Oppenheimer
marketbeat.com - March 28 at 8:29 AM
Xeris Biopharma Surpasses 2023 Expectations with Strategic Moves Poised for 2024 GrowthXeris Biopharma Surpasses 2023 Expectations with Strategic Moves Poised for 2024 Growth
proactiveinvestors.com - March 18 at 9:49 PM
Heres What Analysts Are Forecasting For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) After Its Annual ResultsHere's What Analysts Are Forecasting For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) After Its Annual Results
finance.yahoo.com - March 9 at 1:59 PM
Xeris Biopharma (XERS) Q4 2023 Earnings Call TranscriptXeris Biopharma (XERS) Q4 2023 Earnings Call Transcript
seekingalpha.com - March 8 at 7:43 PM
Xeris Biopharma Holdings Inc (XERS) Reports Robust Revenue Growth in Q4 and Full Year 2023Xeris Biopharma Holdings Inc (XERS) Reports Robust Revenue Growth in Q4 and Full Year 2023
finance.yahoo.com - March 7 at 2:41 PM
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2023 Earnings Call TranscriptXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2023 Earnings Call Transcript
insidermonkey.com - March 7 at 1:01 PM
Q4 2023 Xeris Biopharma Holdings Inc Earnings CallQ4 2023 Xeris Biopharma Holdings Inc Earnings Call
finance.yahoo.com - March 7 at 12:19 AM
Xeris Biopharma Shares Drop After Weak 4Q ResultsXeris Biopharma Shares Drop After Weak 4Q Results
marketwatch.com - March 6 at 7:18 PM
Xeris Pharmaceuticals GAAP EPS of -$0.10 in-line, revenue of $44.39M beats by $0.84MXeris Pharmaceuticals GAAP EPS of -$0.10 in-line, revenue of $44.39M beats by $0.84M
msn.com - March 6 at 7:18 PM
XERS Stock Earnings: Xeris Biopharma Holdings Meets EPS, Beats Revenue for Q4 2023XERS Stock Earnings: Xeris Biopharma Holdings Meets EPS, Beats Revenue for Q4 2023
investorplace.com - March 6 at 2:00 PM
Xeris Biopharma secures $200M in capital in debt refinancing deal; sees big 4Q revenue jumpXeris Biopharma secures $200M in capital in debt refinancing deal; sees big 4Q revenue jump
proactiveinvestors.com - March 6 at 9:57 AM
Xeris Biopharma (XERS) Reports Q4 Loss, Lags Revenue EstimatesXeris Biopharma (XERS) Reports Q4 Loss, Lags Revenue Estimates
zacks.com - March 6 at 9:16 AM
Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent EventsXeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events
businesswire.com - March 6 at 7:02 AM
Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin CapitalXeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital
businesswire.com - March 6 at 7:00 AM
Why Xeris (XERS) Might Surprise This Earnings SeasonWhy Xeris (XERS) Might Surprise This Earnings Season
zacks.com - March 5 at 10:46 AM
Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
businesswire.com - February 28 at 7:00 AM
3 Breakout Stocks Under $5 to Buy for More Upside3 Breakout Stocks Under $5 to Buy for More Upside
theglobeandmail.com - February 23 at 7:13 PM
Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science ConferenceXeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference
finance.yahoo.com - February 5 at 9:27 AM
Big Game or Small, Heres How to Go About Stalking a TradeBig Game or Small, Here's How to Go About Stalking a Trade
realmoney.thestreet.com - February 3 at 6:45 PM
Xeris inks licensing deal with Amgen on former Horizon drugXeris inks licensing deal with Amgen on former Horizon drug
chicagobusiness.com - January 12 at 9:32 AM
Xeris Biopharma jumps on news of Amgen dealXeris Biopharma jumps on news of Amgen deal
thepharmaletter.com - January 12 at 9:32 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Arbutus Biopharma logo

Arbutus Biopharma

NASDAQ:ABUS
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Eton Pharmaceuticals logo

Eton Pharmaceuticals

NASDAQ:ETON
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Vaccinex logo

Vaccinex

NASDAQ:VCNX
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. Its Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. The company was incorporated in 2001 and is headquartered in Rochester, New York.
Xeris Biopharma logo

Xeris Biopharma

NASDAQ:XERS
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.